All Stories

  1. The year in cardiology: arrhythmias and pacing

    Article • European Heart Journal, January 2020, Oxford University Press (OUP)

    John Camm

  2. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation

    Article • EP Europace, July 2019, Oxford University Press (OUP)

    John Camm

  3. The Thrombosis Research Institute, London

    Article • European Heart Journal, July 2019, Oxford University Press (OUP)

    Keith Fox, John Camm

  4. Left atrial ablation for management of atrial fibrillation: CABANA vs. real-world data. Apples and oranges?

    Article • European Heart Journal, March 2019, Oxford University Press (OUP)

    John Camm

  5. Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban

    Article • Current Medical Research and Opinion, May 2018, Taylor & Francis

    John Camm

  6. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention

    Article • EP Europace, October 2017, Oxford University Press (OUP)

    John Camm

  7. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study

    Article • EP Europace, July 2017, Oxford University Press (OUP)

    John Camm

  8. Female gender as a risk factor for stroke associated with atrial fibrillation

    Article • European Heart Journal, March 2017, Oxford University Press (OUP)

    John Camm

  9. Management of stable angina: A commentary on the European Society of Cardiology guidelines

    Article • European Journal of Preventive Cardiology, July 2016, SAGE Publications

    John Camm

  10. The changing circumstance of atrial fibrillation - progress towards precision medicine

    Article • Journal of Internal Medicine, March 2016, Wiley

    John Camm

  11. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

    Article • European Heart Journal, September 2015, European Society of Cardiology

    John Camm

  12. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation

    Article • EP Europace, June 2015, European Society of Cardiology

    John Camm

  13. Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

    Article • American Heart Journal, November 2014, Elsevier

    John Camm

  14. What is ‘valvular’ atrial fibrillation? A reappraisal

    Article • European Heart Journal, September 2014, European Society of Cardiology

    John Camm

  15. Vagal nerve stimulation in heart failure

    Article • European Heart Journal, August 2014, European Society of Cardiology

    John Camm

  16. The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?

    Article • Current Cardiology Reviews, July 2014, Bentham Science Publishers

    John Camm

  17. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

    Article • Vascular Health and Risk Management, July 2014, Taylor & Francis

    John Camm

  18. Early management of atrial fibrillation to prevent cardiovascular complications

    Article • European Heart Journal, February 2014, European Society of Cardiology

    John Camm